Expert Interview
Examining Bristol Myers Squibb’s Phase 3 SCOUT-HCM for Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Ticker(s): BMY, CYTKInstitution: Columbia University
- Assistant Professor of Pediatric Cardiology at Columbia University Irving Medical Center.
- Treats 20 patients monthly with obstructive hypertrophic cardiomyopathy (oHCM).
- Research is focused on identifying novel genetic causes of cardiomyopathy in children.
How does Camzyos (mavacamten) compare to current standard treatments for adolescents with oHCM?
Added By: dami_adminHow does mavacamten (Camzyos) differentiate from existing standard-of-care therapies for adolescents with obstructive hypertrophic cardiomyopathy in terms of mechanism and clinical outcomes?
Added By: dami_adminHow do you anticipate physician adoption of mavacamten evolving for adolescent patients, and what factors will drive or limit uptake?
Added By: dami_adminWhat key risks, monitoring requirements, or long-term considerations could impact the broader use of mavacamten in this population?
Added By: dami_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
